This variability suggests that PD-1+CD28+CD4+ T cells (a subset of helper T cells co-expressing an exhaustion marker) may act as a “transitionary immune signal”: moderate levels may not provide enough activation to prevent residual foci (contributing to R1), while high levels could still support partial anti-tumor activity (inhibiting progression to R2). This evidence concerns the gene CD28 and neoplasm.